Changes in Oncology Medication Use After Withdrawal of Accelerated Approval
This cohort study assesses changes in cancer drug use after negative confirmatory trials and removal of accelerated approval indications from US Food and Drug Administration–approved labeling.
Authors
- Catherine S. Hwang (ORCID: https://orcid.org/0009-0004-0185-3256)
- Amar H. Kelkar (ORCID: https://orcid.org/0000-0001-7627-8509)
- Aaron Seth Kesselheim (ORCID: https://orcid.org/0000-0002-8867-2666)
- Benjamin N. Rome (ORCID: https://orcid.org/0000-0001-5776-3293)
- Edward R. Scheffer Cliff (ORCID: https://orcid.org/0000-0001-5977-907X)
Institutions
- Brigham and Women's Hospital (US)
- The Royal Melbourne Hospital (AU)
- Harvard University (US)
- Oregon Health & Science University (US)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Dana-Farber Cancer Institute (US)
- VA Portland Health Care System (US)
Publication Details
- Journal
- JAMA Oncology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1001/jamaoncol.2025.0359
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00